TY - JOUR
TI - Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
AU - Oliveira, L.M.A.
AU - Gasser, T.
AU - Edwards, R.
AU - Zweckstetter, M.
AU - Melki, R.
AU - Stefanis, L.
AU - Lashuel, H.A.
AU - Sulzer, D.
AU - Vekrellis, K.
AU - Halliday, G.M.
AU - Tomlinson, J.J.
AU - Schlossmacher, M.
AU - Jensen, P.H.
AU - Schulze-Hentrich, J.
AU - Riess, O.
AU - Hirst, W.D.
AU - El-Agnaf, O.
AU - Mollenhauer, B.
AU - Lansbury, P.
AU - Outeiro, T.F.
JO - npj Parkinson's Disease
PY - 2021
VL - 7
TODO - 1
SP - null
PB - Institute of Geographic Sciences and Natural Resources Research
SN - 2373-8057
TODO - 10.1038/s41531-021-00203-9
TODO - null
TODO - With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD. © 2021, The Author(s).
ER -